rais pt
attend prgo recent investor day manag
discuss consum self-car transform plan updat
model base revis estim consum busi
contribut plan acquisit ranir global compani
invest cost save initi separ rx gener unit
via sale estim reflect all-consum compani
consensu estim like includ rx time decid
model compani attempt valu way like
stick hold gener posit strategi
maintain hold rate await progress transform
plan return sustain growth well uncertainti tie tax
liabil came away meet feel gener posit
compani plan drive valu time also intrigu
potenti transit investor base like increasingli
includ investor analyst cover consumer-ori compani
transit value-cr one set stage
potenti revalu manag deliv plan laid
model growth csca cost save invest
expect improv growth overal consum busi includ
consum self-car america csca consum self-car
csci organ constant-curr basi modest
declin hope improv growth time similar
averag consum comp model compound-annual-growth-rate
csca csci chang also factor plan
cost save increment capit spend
preliminari assumpt ranir acquisit
layer preliminari assumpt plan acquisit ranir
global leader private-label oral care product assum close
revenu compound-annual-growth-rate initi oper margin financi
detail limit character busi accret
csca oper margin base assumpt deal add
annual ep
model rx sale year-end
activ negoti sell rx target separ year-
end although compani could choos spin busi secur
fair valu sale model purpos assum sale
tr target
net tax manag hope get well busi appli proce
debt reduct order reduc leverag prgo target assumpt yield ep
dilut acknowledg uncertainti rout separ time
potenti proce base rx assumpt net proce would neutral
page
expect improv growth overal consum busi includ consum self-car
america csca consum self-car csci organ
constant-curr basi modest declin hope improv growth time
similar averag consum comp model compound-annual-growth-rate csca
csci chang increas rx sale estim base compani outlook
also rais oper margin assumpt csca trim estim csci
reflect increment invest rx base mix note prgo revis segment structur
reflect new model compani diagnost busi israel move csci rx
plan acquisit ranir model close revenu compound-annual-growth-rate
initi oper margin financi detail limit character busi
accret csca oper margin figur summar model chang segment
page
remov rx contribut estim start assum compani sell
busi year-end assum sale price net tax manag hope
get well busi appli net proce debt reduct order
reduc debt/ebitda prgo leverag target model chang corpor tax rate
note could upward pressur rx separ manufactur occur
favor tax jurisdict israel assumpt yield ep dilut figur
assum debt averag interest rate repurchas
page
interest
revenu
page
interest
revenu
page
revenu
page
revenu
page
one world largest over-the-count over-the-counter compani chc
america domin player us store brand market chc intern market
brand over-the-counter product across europ gener busi rx
plan separ order make compani consum focus new ceo murray kessler
join compani octob
hold rate reflect see rel balanc risk/reward profil next
month alway like durabl prgo consumer-focus busi growth
potenti busi less clear particularli us store brand market growth
tepid time prgo decis separ rx busi consum busi
could good long-term decis could take time market fulli assess understand
financi oper merit separ whether affect sharehold
valuat risk
pt assum stock trade ebitda support
dcf analysi wacc termin growth rate downsid risk includ lower growth
consum busi lower store brand penetr volatil store brand demand unforeseen
quality/manufactur issu potenti irish us tax liabil disappoint capit deploy
upsid risk includ higher growth consum busi value-ad strateg initi
multipl expans all-consum remainco follow rx separ execut
compani mention note
gregg gilbert herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
